HEMO — Hemogenyx Pharmaceuticals Share Price
Last trade - 00:00- £6.38m
- £7.48m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.08 | ||
| Price to Tang. Book | 2.46 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -88.99% | ||
| Return on Equity | -154.05% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hemogenyx Pharmaceuticals plc is a preclinical-stage biotechnology company. It is engaged in the discovery, development and commercialization of a suite of products to address problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, with bone marrow or hematopoietic stem cell transplants, and with viral infections. Its products include immunotherapy product candidates for the treatment of acute myeloid leukemia (AML) and other blood malignancies and patient conditioning (the CDX bi-specific antibody and CAR-T therapy), and a cell therapy product for BM/HSC transplantation (the Hu-PHEC). Its lead product, HEMO-CAR-T, is therapy for the treatment of AML in which a patient’s own T-cells, a type of immune cell, are modified to recognize and kill the patient’s cancer cells. CBR is a versatile range of potential treatments based on the methodology of programming immune cells using a type of modifiable synthetic receptor to destroy viral pathogens.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- February 13th, 2013
- Public Since
- November 9th, 2015
- No. of Employees
- 17
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 3,699,539
- Address
- 6th Floor, 60 Gracechurch Street, LONDON, EC3V 0HR
- Web
- https://hemogenyx.com/
- Phone
- Auditors
- PKF Littlejohn LLP
Latest News for HEMO
Upcoming Events for HEMO
Full Year 2024 Hemogenyx Pharmaceuticals PLC Earnings Release
Hemogenyx Pharmaceuticals PLC Annual Shareholders Meeting
Half Year 2025 Hemogenyx Pharmaceuticals PLC Earnings Release
Similar to HEMO
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 21:04 UTC, shares in Hemogenyx Pharmaceuticals are trading at 172.50p. This share price information is delayed by 15 minutes.
Shares in Hemogenyx Pharmaceuticals last closed at 172.50p and the price had moved by -73.05% over the past 365 days. In terms of relative price strength the Hemogenyx Pharmaceuticals share price has underperformed the FTSE All Share Index by -74.11% over the past year.
There is no consensus recommendation for this security.
Find out moreHemogenyx Pharmaceuticals does not currently pay a dividend.
Hemogenyx Pharmaceuticals does not currently pay a dividend.
Hemogenyx Pharmaceuticals does not currently pay a dividend.
To buy shares in Hemogenyx Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 172.50p, shares in Hemogenyx Pharmaceuticals had a market capitalisation of £6.38m.
Here are the trading details for Hemogenyx Pharmaceuticals:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: HEMO
Based on an overall assessment of its quality, value and momentum Hemogenyx Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hemogenyx Pharmaceuticals. Over the past six months, its share price has underperformed the FTSE All Share Index by -68.94%.
As of the last closing price of 172.50p, shares in Hemogenyx Pharmaceuticals were trading -59.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Hemogenyx Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 172.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Hemogenyx Pharmaceuticals' management team is headed by:
- Marc Feldmann - CHM
- Vladislav Sandler - CEO
- Andrew Wright - CTR
- Peter Redmond - NID
- Alexis Sandler - NID